News & Events
Disc Medicine Expands Leadership Team with Industry Veterans to Advance Hepcidin Modulating Therapies Toward the Clinic
Jonathan Yu Named Senior Vice President of Corporate Strategy
William Savage, MD, PhD Appointed Vice President of Clinical Development
Cambridge, Mass. – August 3, 2020 – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced the appointment of Jonathan Yu as Senior Vice President of Corporate Strategy and William Savage, MD, PhD as Vice President of Clinical Development. Together, they will work to build the company’s portfolio and advance its pipeline of hepcidin pathway modulators toward the clinic to treat serious hematologic diseases.
“Both Will and Jonathan bring tremendous expertise to Disc Medicine, and I’m thrilled to welcome them to the team,” said John Quisel, JD, PhD, Chief Executive Officer at Disc Medicine. “Will’s experience in clinical hematology will prove invaluable as we advance our pipeline of novel therapeutic candidates targeting the hepcidin pathway into the clinic, and Jonathan’s extensive business acumen will be a great asset as we continue to grow the company and our portfolio.”
Mr. Yu brings his experience in corporate strategy, commercialization and operations to the Disc team. Prior to joining Disc Medicine, Mr. Yu was a co-founder and Vice President of Corporate Strategy, Finance and Operations for Qpex Biopharma. He has also served in various leadership roles at The Medicines Company, most recently as Vice President of Strategic Planning and Corporate Development, where he was instrumental in the divestiture of commercial-stage infectious disease assets to Melinta Therapeutics and the acquisition and subsequent integration of Rempex Pharmaceuticals. Mr. Yu has also held roles at Acceleron Pharma, SR One, and Johnson & Johnson, spanning commercial planning and assessment, business development and finance. Jonathan received an MBA from the Wharton School of the University of Pennsylvania and an AB in Biochemical Sciences from Harvard College.
“I’m thrilled to join Disc Medicine at such an exciting stage in its growth,” said Jonathan Yu, Senior Vice President of Corporate Strategy. “This is a special opportunity to build on the work of an exceptional founding team and create an innovative company that is specifically for patients who are suffering from hematologic diseases.”
Dr. Savage brings a decade of hematology and transfusion medicine clinical research experience, having worked across academic institutions, biopharma and biotech. Prior to joining Disc Medicine, he served as Senior Medical Director at Magenta Therapeutics, where he managed clinical development activities from preclinical through phase 2 and led regulatory interactions. Prior to Magenta Therapeutics, he was the Global Clinical Development Lead in Hematology at Shire/Takeda. Before transitioning to biotech/biopharma, Dr. Savage was an
Assistant Professor of Pathology at Harvard Medical School/Brigham and Women’s Hospital and Johns Hopkins University School of Medicine, where he trained in pediatric hematology/oncology and transfusion medicine. Dr. Savage received his BA in Biochemistry from Columbia University, his MD from Weill Cornell Medical College and his PhD in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health.
“Historically, patients with serious hematologic diseases have had limited treatment options, and the field has lacked innovation compared to other disease areas,” said Will Savage, MD, PhD, Vice President of Clinical Development at Disc Medicine. “Disc’s unique approach in targeting hepcidin regulation presents a compelling opportunity to bring meaningful new therapies to patients suffering from these conditions.”
Disc Medicine is advancing two therapeutic programs focused on modulating hepcidin expression – a novel, orally administered matriptase-2 inhibitor which increases hepcidin expression to treat iron loading anemias, and a hemojuvelin antagonist monoclonal antibody to reduce hepcidin expression and address anemia in a range of serious inflammatory and hematologic diseases.
###
About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.
Media Contact:
Arleen Goldenberg
Verge Scientific Communications
202.930.4762
agoldenberg@vergescientific.com
More News
Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
WATERTOWN, Mass. (December 13, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments...
read more
Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. (November 3, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments...
read more
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)
WATERTOWN, Mass. (October 31, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments...
read more
Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)
WATERTOWN, Mass. (August 10, 2022) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic candidates...
read more
Gemini Therapeutics and Disc Medicine Announce Merger Agreement
WAYLAND, Mass. and WATERTOWN, Mass. (August 10, 2022) – Gemini Therapeutics, Inc. (Nasdaq: GMTX) (“Gemini”) and Disc Medicine, Inc. (“Disc”), a privately-held,...
read more
Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Myelofibrosis Patients with Severe Anemia
CAMBRIDGE, Mass. (June 23, 2022) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic candidates...
read more
Disc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress
WATERTOWN, Mass. (June 10, 2022) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress
WATERTOWN, Mass. (May 16, 2022) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine Appoints Jay T. Backstrom, M.D., M.P.H., to its Board of Directors and Rahul Khara, Pharm.D., J.D., as General Counsel
CAMBRIDGE, Mass. (January 4, 2022) - Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for...
read more
Disc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. (November 11, 2021) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for...
read more
Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
CAMBRIDGE, Mass. (September 2, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for...
read more
Disc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline
CAMBRIDGE, Mass. (August 23, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for...
read more
Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation
CAMBRIDGE, Mass. (July 28, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapies for the...
read more
Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis
CAMBRIDGE, Mass. (May 27, 2021) – Disc Medicine, Inc. announced today that it has entered into an exclusive worldwide licensing agreement with...
read more
Disc Medicine to Present at the European Hematology Association (EHA) 2021 Virtual Congress
CAMBRIDGE, Mass. (May 24, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. (May 21, 2021) – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious...
read more
Disc Medicine Appoints William White to its Board of Directors
CAMBRIDGE, Mass. (January 13th, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. (December 2, 2020) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference
CAMBRIDGE, Mass. (November 23, 2020) – Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for...
read more
Disc Medicine Expands Scientific Advisory Board with Leading Experts in Hepcidin Biology
Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD to Join Disc Medicine Scientific Advisory Board Cambridge, Mass. – October 13, 2020 –...
read more
Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference
Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates...
read more
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that...
read more
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic...
read more
Disc Medicine Expands Pipeline Focused on Hepcidin Pathway
Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicine,...
read more
Introducing Disc Medicine, a New Hematology Company
Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions...
read more